HIV-1 specific T cell

HIV-1 specific T cells refer to lymphocytes that are primed to recognize HIV-1 derived antigens, primarily via the T cell receptor's interaction with peptide-HLA complexes on the surface of infected cells. Both CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ helper T cells play critical yet distinct roles: CD8+ T cells mediate direct killing of HIV-infected cells and regulate viral load, while CD4+ T cells provide essential help for other immune cells, including B cells, but are themselves the principal target of HIV infection, leading to immunodeficiency. The breadth and strength of these T cell responses are essential for viral control, and their dysfunction or depletion underpins HIV pathogenesis. As such, enhancing HIV-1 specific T cell responses is a major goal of therapeutic and vaccine strategies—including the development of antigen-specific adoptive T cell therapies such as CAR-T cells for HIV-1.

Other names

HIV-specific T cellHIV-1 specific CD8+ T cellHIV-1 specific CD4+ T cellHIV-1 CTLHIV-1-specific cytotoxic T lymphocyte

HIV-1 specific T cells operate by recognizing HIV-derived peptides presented on HLA class I molecules via their T cell receptor (TCR). This recognition triggers the release of cytolytic granules like perforin and granzymes to lyse infected cells, and the secretion of antiviral cytokines (e.g., IFN-γ, TNF, IL-2) which directly suppress viral replication and activate other immune cells. In the context of therapy, engineered T cells can also be used for adoptive immunotherapy through antigen-specific CAR-T approaches.